Latest News & Updates

Breaking News

  • 15 hours ago

  • Team Pharma Now

USFDA Completes Inspection of Anuh Pharma’s Facilities Without Form 483 Observation
Breaking News
Roche’s Fenebrutinib Matches OCREVUS In Phase III PPMS Study, Shows Disability-Risk Reduction, Data Highlight Fenebrutinib’s Potential In Progressive Multiple Sclerosis

Vaibhavi M.

Other trending news you may like to read

USFDA Completes Inspection of Anuh Pharma’s Facilities Without Form 483 Observation

Anuh Pharma’s Tarapur manufacturing site clears USFDA inspection with no observations, underscoring global GMP compliance.

Team Pharma Now

Pharma Now

Roche’s Fenebrutinib Matches OCREVUS In Phase III PPMS Study, Shows Disability-Risk Reduction, Data Highlight Fenebrutinib’s Potential In Progressive Multiple Sclerosis

Roche’s fenebrutinib matched OCREVUS in Phase III PPMS, reducing disability risk and showing promise as an oral MS therapy.

Vaibhavi M.

Pharma Now

China’s National Medical Products Administration (NMPA) Grants Priority Review To Eisai And Biogen’s Subcutaneous LEQEMBI For Alzheimer’s Disease

China grants Priority Review to Eisai–Biogen’s subcutaneous LEQEMBI, enabling potential at-home weekly dosing for Alzheimer’s patients.

Vaibhavi M.

Pharma Now

Oryzon Doses First Patient In Yale-Led Phase Ib Trial For ES-SCLC Combination, Iadademstat Tested With Radiation And Atezolizumab In Recurrent Small Cell Lung Cancer

Oryzon treats first patient in Yale-led Phase Ib trial of iadademstat with radiation and atezolizumab in ES-SCLC.

Vaibhavi M.

Pharma Now